Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kendall Schick"'
Autor:
Karan Chohan, Olivia Sirpilla, R. Leo Sakemura, Michelle Cox, Mehrdad Hefazi, Truc Huynh, James Girsch, Kendall Schick, Claudia Manriquez Roman, Carli M. Stewart, Kun Yun, Ismail Can, Ekene J. Ogbodo, Long Mai, Brooke Kimball, Stephen M. Ansell, N. Nora Bennani, Patrick B. Johnston, Jonas Paludo, Jose C. Villasboas-Bisneto, Arushi Khurana, Urshila Durani, Yucai Wang, Paul J. Hampel, Allison Rosenthal, Javier Munoz, Eider Moreno, Januario E. Castro, Hemant S. Murthy, Mohamed Kharfan Dabaja, Sameer Parikh, Neil Kay, Yi Lin, Elizabeth L. Siegler, Saad S. Kenderian
Publikováno v:
HemaSphere, Vol 7, p e07303db (2023)
Externí odkaz:
https://doaj.org/article/31c0139a73454618b647bd71cdefdd63
Autor:
John Copland, Kendall Schick, Justyna Gleba, Truc Huynh, James Miller, Erin MIller, Aylin Alasonyalilar Demirer, Erin Tapper, Reona Sakemura, Elizabeth Siegler, Michelle Cox, Carli Stewart, Ismail Can, Ekene Ogbodo, Claudia Manriquez Roman, Bezerra Evandro, Cui Gaofeng, Mer Georges, Olivier Gloria, Yushi Qui, Robert Smallridge, Abba Zubair, Han Tun, Saad Kenderian
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Michelle Cox, Mehrdad Hefazi, Neil E. Kay, Kendall Schick, Sutapa Sinha, Reona Sakemura, Fabrice Lucien-Matteoni, Nan Yang, Cynthia Forsman, Justin Boysen, Saad S. Kenderian, Sameer A. Parikh
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:YIA19-003
Background: Unprecedented clinical outcomes were reported after CD19 chimeric antigen receptor T-cell (CART19) therapy. However, the complete response rate in chronic lymphocytic leukemia (CLL) is much lower, at approximately 20%–30%. Several immun
Autor:
Cynthia Forsman, Saad S. Kenderian, Justin Boysen, Neil E. Kay, Michelle Cox, Kendall Schick, Sutapa Sinha, Nan Yang, Mehrdad Hefazi, Wei Ding, Sameer A. Parikh, Michael Hansen, Reona Sakemura
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:YIA19-002
Despite the remarkable outcomes of CD19-directed chimeric antigen receptor T (CART19) cell therapy in B-cell malignancies, the durable responses in diffuse large B-cell lymphoma are less than 40%, and strategies to enhance this response are desperate